Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) have developed a cell line that stably over-expresses GPR101. GPR101 inhibitors and agonists may be used to treat gigantism, acromegaly or dwarfism.
The NICHD seeks licensing and/or co-development research partners to collaborate on the identification and characterization of GPR101 inhibitors (antagonists and inverse agonists) and agonists with the goal of identifying agents to treat gigantism, acromegaly or dwarfism.
The Laboratory of Cardiovascular Sciences of the National Institute on Aging, is seeking parties interested in licensing or collaborative research to co-develop a cell surface protein observed to reduce inflammation and related injuries. In vivo and in vitro data are available.
The National Cancer Institute seeks parties interested in collaborative research to co-develop or license methods of treating disorders related to polyomavirus, as well as vaccines for patients undergoing immunosuppressive treatment such as multiple sclerosis, rheumatoid arthritis, B cell cancers, and Crohn’s disease.
The Laboratory of Cardiovascular Science at the National Institute on Aging, is seeking parties interested in collaborative research to further co-develop a potential new hypertensive drug based on recombinant human erythropoietin (rhEPO).
Researchers at the NCI have developed chimeric antigen receptors (CARs) with a high affinity for VEGFR2. Many cancers and solid tumors from endothelial cells overexpress VEGFR2 making that prime targets for treatment with these specific CARs.
NIH scientists created and characterized an excellent mouse model for TNBC that shares important molecular characteristics of human TNBC making it highly useful for preclinical testing of drugs and novel therapies. This model may provide a valuable means of identifying new drugs and therapies that could be translated to human clinical trials.The NCI seeks parties interested in licensing this mouse model of prostate and triple-negative breast cancers to study cancer biology and for preclinical testing.
Researchers at the National Institute on Aging (NIA) have developed a novel strategy for rendering weakly or non-immunogenic, shared (between self and tumor) antigens immunogenic, or able to produce an immune response. Further, they have created therapeutic polypeptides comprising tumor-associated embryonic antigens and chemoattractant ligands. Cancers targeted by these developments include breast, renal, lung, ovarian, and hematological cancers.
The National Institutes of Health, through The National Institutes of Health - Clinical Center (NIH-CC) and the National Heart Lung and Blood Institute (NHLBI), seeks licensing and/or co-development partners for a nitric oxide cream for the treatment of ulcers associated with sickle cell disease.
Currently available topical antibiotic formulations effectively eliminate bacteria at a wound site. Eliminating bacteria in the wound also eliminates the molecular signals present in bacterial DNA that stimulate the immune system's wound healing processes. Without these signals, the rate of wound healing is diminished. The National Cancer Institute Laboratory of Experimental Immunology seeks parties interested in licensing or collaborative research to further co-develop a topical antibiotic formulation to accelerate wound healing.
Researchers at the National Cancer Institute (NCI) seek licensing for an improved cell line called Tni-FNL which is capable of high level expression of heterologous proteins using baculovirus expression systems.
This surgical clamp device is particularly useful for intraocular surgeries requiring incision in the sclera. The device provides ease of use for repeated opening and closure of an incision or wound for entry of instruments into the eye. It maintains precise alignment of the wound margins, reducing loss of intraocular fluid and pressure. The NEI seeks licensees or collaborative co-development of this invention so that it can be commercialized.
Novel thalidomide analogs and their use as immunomodulatory agents are disclosed in this invention by scientists at the National Institute on Aging (NIA). These therapeutic compounds could reduce chronic systemic and central nervous system inflammation. The NIA seeks licensing or co-development partners to commercialize this technology.
The Section on Translational Neuroscience of NICHD seeks parties interested in licensing and/or collaborative research to co-develop this therapeutic management of Menkes Disease and related copper transport disorders.
Researchers at the National Cancer Institute (NCI) have developed a combination of immunoadjuvants and immune checkpoint inhibitors to stimulate an immune response against cancer. The combination therapy has been tested in xenograft models and shown successful for both treatment of an existing tumor and resistance to re-challenge. Researchers at the NCI seek licensing and/or co-development research collaborations for this invention.
Available for licensing and co-development are antibody-drug conjugates (ADC) that incorporate one of two novel human CD56 antibodies, known as m900 and m906, in combination with a known cytotoxic drug, pyrrolobenzodiazepine (PBD).
Researchers at the National Cancer Institute (NCI) have developed an invention describing the binding domain (G2BD) for the ubiquitin-conjugating enzyme Ube2G2 in the gp78 ubiqutin ligase protein. The invention involves modulating the interaction between the gp78 protein and the conjugating enzyme Ube2G2. Interruption of this interaction will block degradation from the endoplasmic reticulum (ER), resulting in ER stress, unfolded protein response, and, ultimately, apoptosis in some cancer cells. The NCI seeks licensing and/or co-development partners for this invention.
The Biorepositories and Biospecimen Research Branch (BBRB) at the National Cancer Institute (NCI) has sponsored various initiatives for conducting biospecimen research. Through these initiatives, NCI seeks to advance biospecimen science and improve research reproducibility by investigating how different biospecimen collection, handling and processing procedures affect biospecimen molecular profiles. BBRB is seeking collaborators to extend these studies.
Researchers at the National Cancer Institute (NCI) have developed a method to improve the function of therapeutic engineered T cells used for Adoptive T Cell Therapy (ACT) for various cancers and diseases through the co-expression of Interleukin-15 (IL-15) and IL-21 by a flexible linker to the cell membrane. Researchers at the NCI seek licensing and/or co-development research collaborations for this invention.